Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

September 24, 2026 updated by: Quoin Pharmaceuticals

A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

16

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United Kingdom
      • London, United Kingdom, SE1 9RT
        • Recruiting
        • Guy's Hospital, Skin Therapy Research Unit
        • Contact:
    • England
      • London, England, United Kingdom, WC1N 3JH
        • Recruiting
        • Great Ormond Street Hospital, NIHR - Clinical Research
        • Contact:
    • West Midlands
      • Walsall, West Midlands, United Kingdom, WS2 9PS
        • Recruiting
        • Walsall Manor Hospital, Research & Development
        • Contact:
  • United States
    • California
      • Fremont, California, United States, 94538
        • Recruiting
        • Center for Dermatology Clinical Research
        • Contact:
    • Connecticut
      • New Haven, Connecticut, United States, 06520
        • Not yet recruiting
        • Yale University School of Medicine
        • Contact:
    • Indiana
      • Indianapolis, Indiana, United States, 46250
        • Recruiting
        • Dawes Fretzin Clinical Reseacrh Group
        • Contact:
    • Massachusetts
      • Quincy, Massachusetts, United States, 02169
    • Texas
      • San Antonio, Texas, United States, 78218
        • Recruiting
        • Texas Dermatology and Laser Specialists
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Participant is male or female and at least 4 years of age.
  2. Participant has provided written informed consent/assent. Based on the participant's age and local regulations , a participant under legal age of consent must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the participant. If a participant reaches the age at which consent is required by local regulations during the study, the participant must provide written informed consent at that time to continue study participation.
  3. Female participants must either not have experienced menarche, be postmenopausal , or be surgically sterile , or use a highly effective method of birth control , for the duration of the study and for 3 months following EOT. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline. Males must use a condom in addition to having their female partner use a highly effective method of birth control.
  4. Participant has a genetically confirmed diagnosis of NS prior to Visit 2/Baseline. Participants without existing results must undergo genetic testing at Visit 1/Screening, which must confirm the diagnosis of NS in order for the participants to be enrolled in the study.

Exclusion Criteria:

  1. Participant is pregnant, lactating, or is planning to become pregnant during the study.
  2. Participant has active cancer of any type excluding melanoma skin cancer outside of the Treatment Area.
  3. Participant has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled, in the opinion of the investigator.
  4. Participant has evidence of active infection during Screening, or serious infection within 30 days prior to Visit 2/Baseline.
  5. Participant has known human immunodeficiency virus, hepatitis B or C virus, or active or latent tuberculosis.
  6. Participant has ongoing or recent history of any other uncontrolled and/or clinically significant systemic disease or condition which, in the opinion of the investigator, should exclude participation in the study.
  7. Participant has used ultraviolet phototherapy within the Treatment Area within 4 weeks prior to Visit 2/Baseline.
  8. Participant has used systemic non-biologics prescription treatment for NS or that in the opinion of the investigator may affect the participant's NS (examples include, but are not limited to antibiotics, retinoids, etc.) within 4 weeks prior to Visit 2/Baseline.
  9. Participant has used systemic biologic therapy for NS or that in the opinion of the investigator may affect the participant's NS within 5 half-lives of the biologic therapy prior to Visit 2/Baseline. Published or documented half-life of the product provided by the commercial supplier or Sponsor should be used to establish this value.
  10. Participant has used topical prescription treatments, including steroids (examples include, but are not limited to keratolytics, steroids, retinoids, etc.) in the Treatment Area within 2 weeks prior to Visit 2/Baseline.
  11. Participant has used any topical bland moisturizers/emollients in the Treatment Area within 24 hours prior to Visit 2/Baseline.
  12. Participant is currently enrolled in an investigational drug, biologic, or device study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: QRX003 lotion, 4% BID

Subjects will apply test article twice daily (BID) for 12 weeks
Drug: QRX003

Serine Protease Inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects with 1-point reduction on IGA
Time Frame: Week 12

The IGA (Investigator Global Assessment) is a 5-point scale used to assess the overall severity of a Subject's NS condition.
Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of subjects with 2-point improvement on the WI-NRS
Time Frame: Week 12

Subjects will rate their itch intensity using the 11-point Worst-Itch-Numeric Rating Scale (WI-NRS)
Week 12
PGI-C Score
Time Frame: Week 12

Patient (or Caregiver) Global Impression of Change (PGI-C) is a 7-point, self-assessed scale measuring the patient's (or caregiver's) improvement of their NS condition.
Week 12
CGI-C Score
Time Frame: Week 12

Clinical Global Impression of Change (PGI-C) is a 7-point scale used by the clinician to assess improvement of the NS condition.
Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Quoin Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 19, 2026

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

March 24, 2026

First Submitted That Met QC Criteria

April 15, 2026

First Posted (Actual)

April 20, 2026

Study Record Updates

Last Update Posted (Actual)

September 28, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CL-QRX003-004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe